Filing Details
- Accession Number:
- 0001601830-24-000083
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-17 17:46:49
- Reporting Period:
- 2024-06-13
- Accepted Time:
- 2024-06-17 17:46:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1855980 | Michael Secora | C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2024-06-13 | 39,375 | $2.22 | 1,258,468 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-06-13 | 15,000 | $9.32 | 1,243,468 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-06-14 | 39,375 | $2.22 | 1,282,843 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-06-14 | 15,000 | $9.27 | 1,267,843 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-06-13 | 39,375 | $0.00 | 39,375 | $2.22 |
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-06-14 | 39,375 | $0.00 | 39,375 | $2.22 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 770,760 | 2030-03-03 | No | 4 | M | Direct | |
| 731,385 | 2030-03-03 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | $2.22 | 2030-03-03 | 0 | 685,177 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2022-02-04 | 2032-02-04 | 0 | 3,914 | Direct |
| Class A Common Stock | Stock Option (Right to Buy) | $11.40 | 2032-02-04 | 0 | 116,684 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $8.55 | 2033-02-01 | 0 | 404,857 | Direct | |
| Class A Common Stock | Stock Option (Right to Buy) | $10.09 | 2034-02-09 | 0 | 348,380 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2030-03-03 | 0 | 685,177 | Direct |
| 2032-02-04 | 0 | 3,914 | Direct |
| 2032-02-04 | 0 | 116,684 | Direct |
| 2033-02-01 | 0 | 404,857 | Direct |
| 2034-02-09 | 0 | 348,380 | Direct |
Footnotes
- Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.
- This transaction was executed in multiple trades at prices ranging from $9.125 to $9.47 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $9.185 to $9.39 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
- The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Billionaire Hedge Funds
